Improved progression-free survival for lutathera over octreotide
Saturday, June 4, 2016 - 05:31
in Health & Medicine
Researchers will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs).